Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Sanofi is dedicated to supporting people through their health challenges. We are a...
Sanofi is dedicated to supporting people throug...
Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai...
Cellect Biotechnology Ltd. was founded in 2011 ...
Opiant is a specialty pharmaceutical company developing medicines for addiction an...
Opiant is a specialty pharmaceutical company de...
Medigus is a medical device company specializing in developing minimally invasive ...
Medigus is a medical device company specializin...
Myriad Genetics, Inc., is a leading precision medicine company dedicated to being ...
Myriad Genetics, Inc., is a leading precision m...
Genmab is a publicly traded, international biotechnology company specializing in t...
Genmab is a publicly traded, international biot...
China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company based in T...
China SXT Pharmaceuticals, Inc. is an innovativ...
Join the National Investor Network and get the latest information with your interests in mind.